Starling Oncology, Inc. (STLNW) Capital expenditures 2020–2025
Starling Oncology, Inc. (STLNW) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$3.2MFY2025 · since FY2020: $1.2M → $3.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.2M | -15.5% |
| FY2024 | $3.8M | -17.0% |
| FY2023 | $4.6M | -17.4% |
| FY2022 | $5.5M | +94.2% |
| FY2021 | $2.8M | +138.4% |
| FY2020 | $1.2M | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →